A rancid culprit in vascular inflammation acts on the prostaglandin receptor EP2.
Norbert
N
Leitinger
D050197:Atherosclerosis / Q000209:etiology*; D000242:Cyclic AMP / Q000502:physiology; D015232:Dinoprostone / Q000494:pharmacology; D006801:Humans; D028421:Isoprostanes / Q000494:pharmacology; D010084:Oxidation-Reduction; D010713:Phosphatidylcholines / Q000494:pharmacology; D010741:Phospholipases A / Q000502:physiology; D010742:Phospholipid Ethers / Q000378:metabolism / Q000494:pharmacology*; D018078:Receptors, Prostaglandin E / Q000187:drug effects* / Q000502:physiology; D058307:Receptors, Prostaglandin E, EP2 Subtype
C400184:1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; C500237:1-palmitoyl-2-(epoxyisoprostane-E2)-sn-glycero-3-phosphocholine; D028421:Isoprostanes; C545644:PTGER2 protein, human; D010713:Phosphatidylcholines; D010742:Phospholipid Ethers; D018078:Receptors, Prostaglandin E; D058307:Receptors, Prostaglandin E, EP2 Subtype; D000242:Cyclic AMP; D010741:Phospholipases A; D015232:Dinoprostone